Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

NCT02207634 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02207634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02207634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
September 10, 2014
Completion date
November 11, 2016
Enrollment
1,974 (actual)
Sites
416

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia